Compare AARD & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AARD | WHF |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 138.7M |
| IPO Year | 2025 | 2012 |
| Metric | AARD | WHF |
|---|---|---|
| Price | $7.21 | $7.14 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 9 | 2 |
| Target Price | ★ $15.29 | $7.75 |
| AVG Volume (30 Days) | ★ 137.9K | 49.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.67% |
| EPS Growth | ★ 43.11 | 31.91 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $6.07 |
| 52 Week High | $17.94 | $8.97 |
| Indicator | AARD | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 71.97 |
| Support Level | $4.99 | $7.08 |
| Resistance Level | $7.92 | $7.55 |
| Average True Range (ATR) | 0.71 | 0.18 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 60.28 | 98.80 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.